Short term sodium alendronate administration improves the periimplant bone quality in osteoporotic animals Sodium alendronate is a bisphosphonate drug that exerts antiresorptive action and is used to treat osteoporosis. Objective: The aim of this study was to evaluate the bone repair process at the bone/implant interface of osteoporotic rats treated with sodium alendronate through the analysis of microtomography, real time polymerase chain reactions and immunohistochemistry (RUNX2 protein, Material and Methods: A total of 42 rats were used and divided in to the following and fed with a balanced diet), OST: osteoporosis group (rats submitted to a bilateral ovariectomy and fed with a low calcium diet) and ALE: alendronate group (rats submitted to a bilateral ovariectomy, fed with a low calcium diet and treated with sodium alendronate). A surface treated implant was installed in both tibial metaphyses of each rat. Euthanasia of the animals was conducted at 14 (immunhostochemistry) and 42 days (immunohistochemistry, micro CT level. Results: Bone volume (BV) and total pore volume were higher for ALE expressed in the ALE group (P<0.05), in comparison with the other groups.
Introduction
Rehabilitation with dental implants has become widespread in society and most of the patients demanding this treatment are above 60 years old, a life stage in which osteoporosis is very common, especially in women 7 . Studies regarding dental implants in osteoporotic patients claim that the osteoporotic bone is similar to the proposed model of type IV bone, that is, residual bone formed by a thin layer of cortical bone surrounding the low density cancellous bone.
quality, ranging from type I to IV 13 . Because of this, some authors contraindicate the use of implants in patients with osteoporosis, while others believe it is not a determining factor to contraindicate therapy with dental implants since the professional performs an larger diameter, implant surface treatment and a longer waiting period for prosthetic load application 13, 14 .
Regarding to the impact of osteoporosis on dental implant survival, Chen, et al. 8 (2013) and Busenlechner, et al. 5 (2014) reported that since there is no statistically significant differences between osteoporotic and non-osteoporotic patients that had been rehabilitated with dental implants, there is a strong correlation between this bone metabolism condition and implant survival, mainly in the mandible. These studies did not include a feasible number of patients to establish a comparison between osteoporotic and non-osteoporotic patients. Besides that, these clinical studies did not show indicate drugs used for osteoporosis.
Currently, several therapies are available for the treatment of osteoporosis, however, they present some
The role of estrogen in bone integrity maintenance has been recognized for a while, although estrogen including vascular events and breast carcinoma 5 .
Some drugs act by decreasing bone resorption and therefore delaying bone loss rate (antiresorptive therapy), such as bisphosphonates, calcitonin and the human monoclonal antibody, denosumab, or by promoting bone formation (anabolic therapy), such as teriparatide 1, 3, 14, 18, 19, 28 . .
Several studies investigated the effects of the oral bisphosphonates in osteoporosis conditions related to 1, 4, 6, 14 , bone mineral density 3, 6, 9, 20, 28 , bone strength 3, 28 and bone repair 2, 7, 11, 19 . For the quantitative analysis (micro CT and PCR), after the Power Test calculation, the sample number for each group was a minimum of 6 (power test=0.8).
Thus, as PCR was made in quadruplicate, we elected 4 animals (left tibia) for this evaluation. For the micro CT evaluation, 6 animals were selected (4 right tibia belonging to the PCR groups plus 2 animals) with a total number of 18 animals.
For the qualitative analysis (immunhoistochemical), 4 animals per group were selected for the periods (14 and 42 days). Thus, we had obtained 24 animals.
(N=42). From the CTL group, only the ovary exposure was performed.
The rats from the OST and ALE groups were fed with a low calcium diet (containing 0.1% Ca, 0.5% P and water ad libitum) and the CTL group was fed with a balanced diet containing 1.4% Ca, 0.8% P and water ad libitum.
The low calcium and phosphate diet was used in order to simulate a real osteoporosis situation.
According to previous studies 21, 26, 27 , when rats were subjected to bilateral ovariectomies and fed with low calcium diet, there was a decrease of bone mineral density up to two higher greater. Thus, only those undergoing ovariectomy surgery could have an osteopenia condition.
Sodium alendronate
Eight days after ovariectomy, the drug therapy sodium alendronate dissolved in an aqueous solution to the ALE group, as designed by Paz, et al. 20 (2001) , and gavage with saline solution to the OST and CTL groups. This treatment was conducted until the end of the experiment.
Implants
After fasting for eight hours, the animals were In order to collect material, the animals were anesthetized following the anesthesia protocol for implant placement. Then, the implants of left tibias were removed by counter-torque and the bone material that was previously in contact with the implant was collected for RT-PCR analysis (real time polymerase chain reaction). At this moment, the rats were euthanized as outlined by Ramalho-Ferreira, et al. 22 (2015) and the right tibias were removed and reduced with margins of about 1 cm to perform the Micro-CT analysis.
Microtomography evaluation (Micro-CT)
For the three-dimensional analysis of animals from the CTL, OST and ALE groups after euthanasia, at the 42-day period, the right tibias that had been removed were analyzed in periods of 14 and 42 days. 
Results

Micro-Ct
The pieces' scans were made in the CTL, OST and ALE groups, 42 days after implant placement. 
Immunohistochemical analysis
Immunohistochemical analysis performed at 14 and 42 days can be observed by the staining scores (Figure 3 ). 1, 4, 7, 14, 20 . Apparently, according to previous studies 7, 11, 12, 19, 28 , sodium alendronate is also able to improve bone repair at the bone/implant interface under osteoporosis conditions, at least at the beginning of the bone tissue evaluation.
resorptive potential of ALE in lower quality bones.
Considering the molecular and immunohistochemical results, the staining observed for RUNX2 showed lightly to moderately expressed pre-osteoblasts at 14 days in the OST group, presenting an increase in transcription factor expression, perhaps in an attempt to recruit a greater number of osteoblasts, offsetting the decrease in osteoblast activity due to the osteoporosis installed on this experimental group. The ALE group showed similar results to the CTL group, 
